In this single institution retrospective study, we reviewed 950 consecutive patients with prostate adenocarcinoma receiving definitive radiotherapy between 2011 and 2019, and identified among them 112 patients with anatomic variations (edge cases) seen on simulation CT and/or MRI imaging. These variations included hip arthroplasty, prostate median lobe hypertrophy, so-called “droopy” seminal vesicles, presence...
This collection contains longitudinal PET/CT and quantitative MR images collected for the purpose of studying treatment assessment in breast cancer in the neoadjuvant setting. Images were acquired at three time points: prior to the start of treatment (t1), after the first cycle of treatment (t2), and either after the second cycle of treatment or at the completion of all treatments (prior to surgery) (t3). The PET/CT...
This collection contains subjects from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium Uterine Corpus Endometrial Carcinoma (CPTAC-UCEC) cohort. CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics....
Adrenocortical carcinoma (ACC) is a rare tumor of the adrenal cortex with a reported annual incidence of one case per million population. ACC is a highly aggressive, highly fatal tumor with 5-year overall survival rates ranging from 14% to 44%. Diagnosis of ACC is primarily based on histopathological parameters from resected tumors, which include Ki-67 expression status. The Ki-67 index is one of the most important...
This collection of breast dynamic contrast-enhanced (DCE) MRI data contains images from a longitudinal study to assess breast cancer response to neoadjuvant chemotherapy. Images were acquired at four time points: prior to the start of treatment (Visit 1, V1), after the first cycle of treatment (Visit 2, V2), at midpoint of treatment course (Visit 3, V3), and after completion of treatment (prior to surgery) (Visit 4,...
Expensive and lengthy clinical trials delay regulatory evaluation of innovative medical technologies affecting patient access to high-quality medical products. Sophisticated simulation tools are increasingly being used in device development, but are rarely used in regulatory applications. We investigate a new paradigm for evaluating digital breast tomosynthesis (DBT) as a replacement for digital mammography (DM), using...
